Product
JAB-BX102
Aliases
JAB-BX102 (anti-CD73 monoclonal antibody)
1 clinical trial
1 indication
Indication
Solid TumorClinical trial
A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-03-01